It is generally assumed that the major causes of in vitro fertilization (IVF) failure in women with endometriosis are diminished ovarian reserve, impaired endometrial receptivity and low quality of embryos. The use of prolonged courses of hormone therapy may play an important role in the strategy of overcoming endometriosis-related infertility. The aim of this study was to evaluate the use of dienogest (DNG) before an IVF cycle in women with endometriosis undergone a previous IVF failed cycle
The primary outcomes of the study are clinical pregnancy rate and live birth rate after reaching 24 week's gestation. Secondary outcomes of the study are: changes in the diameter and volume of the largest endometrioma, total gonadotropin dose administered, number of mature oocytes collected, number of two-pronuclear (2PN) embryos, number of blastocysts.
Study Type
OBSERVATIONAL
Enrollment
140
Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
IRCCS Ospedale Policlinico San Martino
Genoa, Italy
Clinical pregnancy rate
Time frame: 8 weeks
Live birth rate after reaching 24 week's gestation
Time frame: 24 weeks
Total gonadotropin dose administered
Time frame: During the procedure
Number of mature oocytes collected
Time frame: During the procedure
Number of two-pronuclear (2PN) embryos
Time frame: During the procedure
Number of blastocysts.
Time frame: During the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.